MLH3 Deficient Expression
MLH3 Deficient Expression serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains MLH3 Deficient Expression as an inclusion criterion, 1 is phase 2 (1 open).
Trials with MLH3 Deficient Expression in the inclusion eligibility criteria most commonly target prostate adenocarcinoma and prostate small cell carcinoma .
Pembrolizumab is the most frequent therapy in trials with MLH3 Deficient Expression as an inclusion criteria .
Significance of MLH3 Deficient Expression in Diseases
Prostate Adenocarcinoma +
MLH3 is altered in 2.87% of prostate adenocarcinoma patients .
MLH3 Deficient Expression is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 Deficient Expression and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Prostate Small Cell Carcinoma +
MLH3 Deficient Expression is an inclusion criterion in 1 clinical trial for prostate small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 Deficient Expression and prostate small cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.